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retrieved from the G-BA homepage (https://www.g-ba.de/informationen/nutzenbe-
wertung/). Cut-off date for assessment inclusion was May 15th 2015. The following 
sources for extraction had to be available: Dossier module 3 (pharmaceutical com-
panies), G-BA decision/rationale (G-BA). Extraction included assessment date/type, 
active substance, indication(s), therapeutic area, target population in total/subgroups 
(min, max, exact) and data sources. Missing exact numbers were calculated from min/
max. For the analysis indications/subgroups clearly differing by written definition 
were excluded. Results: 147 indications were included. Overall the mean devia-
tion for the target population was 39 % (exact number, positive/negative differences 
included). Mean deviations by year were 42 % (2011), 15 % (2012), 65 % (2013) and 35 
% (2014/2015). Therapeutic areas with the highest deviations concerned “Infectious 
Diseases” (110 %), “Metabolic Diseases” (51 %) and “Oncology” (28 %). These areas 
accounted for 9, 34 and 27 % of the 147 assessments, respectively. Further results on 
e.g. min/max, subgroups, sensitivity analyses excluding deviations ≥ 80 % (signaling 
a difference in definition) will be presented. ConClusions: Epidemiological data 
presented by pharmaceutical companies and G-BA differs considerably. A learning 
curve from 2011 to 2014 is not clearly visible. Susceptible therapeutic areas with high 
deviations are infectious diseases, metabolic diseases and oncology. The poster will 
discuss possible reasons, including data sources.
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Prices cHanges for Patent-Protected innovative drugs in tHe toP 5 
eu PHarmaceutical markets
Reinaud F1, Ando G2
1IHS Life Sciences, Paris, France, 2IHS Life Sciences, London, UK
objeCtives: Identify within the top 5 EU countries where innovative pharmaceuti-
cal prices decrease the most. Methods: Average price changes over time as well as 
average time to first price cuts were analysed for pharmaceuticals approved by the 
European Medicines Agency (EMA), priced in each market in 2009 and afterwards, 
which are still patent-protected and reimbursed in all analysed markets. Results: 
Overall, the majority of the innovative drugs that are reimbursed and still patent-
protected have not experienced a price change in each of the market studied since 
2009. Over the period analysed, Germany and France are the countries where the 
largest number of innovative drugs experienced a price cut (around 37% of the 
samples analysed for both countries). Price cuts commonly occur after 1.2 year 
on average in Germany and 1.7 year in France. Drugs assessed under the AMNOG 
reform in Germany saw their prices drop by an average of 17%. In Italy, Spain and 
the United Kingdom, the part of innovative pharmaceuticals experiencing price 
cuts is more limited, 10.6%, 12.9% and 16.9%. Additionally, the average price cut is 
small. ConClusions: Within the EU top 5, price cuts for innovative pharmaceuti-
cals are more likely to be implemented in Germany as well as in France. In Germany, 
the AMNOG reform has had a significant impact on prices of drugs that completed 
the process. In France, the majority of the price cuts occurred for drugs that are not 
deemed innovative (ASMR rating of IV or V); which are therefore not granted the 
European level price guarantee for a five-year period. In Italy, Spain and the United 
Kingdom, price cuts do not occur regularly, at least at the list level. Other studies 
have demonstrated that prices tend to be lower at launch but are more likely to 
remain constant over time.
PHP14
outPatient utilization and Quality aPPraisal of antibiotics in 
turkey
Demir C, Gursoy K, Ozturk Y, Koselerli R
Turkish Social Security Institution, Ankara, Turkey
objeCtives: Antibiotic use is of great importance in terms of public health since 
misuse can result in antibiotic resistance. Therefore, evaluating antibiotic consump-
tion is essential. The objective of this study is to analyze the outpatient utiliza-
tion and measure the quality of antibiotic use in Turkey. Methods: Data on the 
total outpatient consumption of antibacterials for systemic use (J01) from 2010 to 
2013 were aggregated from the Turkish Social Security Institution (SGK) at the level 
of active ingredient and then expressed in Defined Daily Doses (DDD) per 1000 
inhabitant per day according to WHO guideline. Annual growth rates of utilization 
were examined. Moreover, 5 of the ESAC Quality Indicators for Consumption of 
Antimicrobials for Systemic Use were computed according to ECDC Survelliance 
Report 2012. Results: While utilization in 2011 boosted by 28% and reached 37 
DDD per 1000 inhabitants per day mostly due to the new drug penetration to the 
market, the figure reduced to 35 in 2013, the highest among EU countries. J01C 
ATC-3 group received the largest share (43,5%) from the total J01 consumption, 
followed by J01D and J01F, all three constituting nearly 88%. As quality indicators, 
relative use of beta lactamase-sensitive penicillins (J01CE_%) and fluoroquinolones 
(J01MA_%) shrank in each year whereas the ratio of broad to narrow spectrum 
antibacterials rose from 11 in 2010 to 17,1 in 2013. Additionally, relative use of com-
binations of penicillins including beta-lactamase inhibitors (J01CR_%) and third 
and fourth-generation cephalosporins (J01DD+DE_%) reached to 37,5% and 13,3% 
respectively in 2013, all indicating misprescribing and hence leading to antibiotic 
resistance. ConClusions: Compared to European countries, antibiotic consump-
tion in Turkey is quite high and there occurs a shift from narrow spectrum antibiot-
ics to broad ones. As a solution, rational drug use and prescription guidelines can 
be policy tools to reduce consumption and improve quality.
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tHe imPact of tHe increasing Penetration of on-Patent medicines on 
tHe greek PHarmaceutical market
Manias NG1, Kyriopoulos I2, Ollandezos M2, Athanasakis K2, Kyriopoulos J2
1MINTE, ATHENS, Greece, 2National School of Public Health, Athens, Greece
objeCtives: From 2001 onwards, a wave of new innovative medicines has been 
introduced in the Greek pharmaceutical market. Based on this, the purpose of this 
study is to identify and quantify the effects of the increasing penetration of innova-
tive medicines on pharmaceutical spending in Greece during the period 2001-2014, 
Prevalence of antibiotic resistant bacteria has steadily increased over the 7-year 
period alongside that of antibiotic usage. Association between antibiotic resistance 
and clinical factors including antibiotic consumption, site of infection and severity of 
infection will be examined and a mathematical model predicting bacterial resistance, 
which controls for these factors, is being constructed.
PHP10
tHe under-recognised Human and economic imPact of cHronic 
rHinosinusitis
Battaglia S1, Annoni E1, Hodge D2, Barnett G1
1Medtronic International Trading Sàrl, Tolochenaz, Switzerland, 2Medtronic Inc., Surgical 
Technologies, Jacksonville, FL, USA
objeCtives: The impact of chronic rhinosinusitis (CRS) on healthcare resources, 
productivity and health-related quality of life (HRQoL) is under-recognized and the 
condition under-treated. The objective of this study was to identify the extent of 
the human and economic impact of CRS. Methods: A comprehensive literature 
search of Medline and EMBASE (2000- January 2015) was performed. Eligibility crite-
ria included patient-reported CRS or a CRS diagnosis, retrospective and prospective 
designs. Abstracts or full text articles were systematically selected if they presented 
data for patients with a diagnosis of CRS, and search terms relevant to CRS, and 
its human and economic burden were applied. Results: The search yielded 786 
titles and ultimately 32 abstracts/articles met the eligibility criteria. People with CRS 
have significantly worse physical, emotional, mental and social HRQoL compared 
to the general population. They are also three times as likely to report their health 
as poor compared to those with another chronic condition, and among those with 
medically refractory CRS, 49% report anxiety/depression, while 31% report problems 
with usual daily activities. In addition, CRS is associated with a significant rise 
in costs due to an increased need for primary/secondary care, emergency room 
visits, and prescription refills. Comparatively, medically refractory CRS resulted 
in a significantly higher indirect cost than diabetes, migraine or severe asthma; 
the cost of lost productivity was estimated to be US$10,077 annually per patient in 
the US, and increased with severity. The longer the time delay between diagnosis 
and sinus surgery (SS), the greater the need for CRS-related visits and prescrip-
tions, rendering delayed SS economically inefficient. However, the cost of managing 
complications of SS (nasal bleeds and cerebrospinal fluid leaks) more than doubles 
the cost of the procedure itself. ConClusions: Results consistently demonstrate 
that CRS imposes a substantial human and economic burden on patients and soci-
ety, especially medically refractory CRS.
HealtH care use & Policy studies – drug/device/diagnostic use & Policy
PHP11
systematic review on use of economic evidence in clinical 
guidelines
Aggarwal S1, Topaloglu H1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, 
USA
objeCtives: The recent reforms and policy changes have increased the cost pres-
sures on all healthcare stakeholders, including clinical experts. In the past, clini-
cal guidelines were developed independent of cost or economic considerations. 
However, increasingly, more clinical guidelines are mentioning cost concerns and 
referring to economic data in new recommendations. The objective of this study 
was to analyze trends in the use of health economic information for developing 
clinical guidelines. Methods: A systematic literature search was undertaken for 
the databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. The guidelines 
published between 2003-2015 were included. For guidelines which met the search 
criteria, data was collected for the name of the authors, indication, year of publi-
cation, country/region, and context of use of cost/economic evidence. Results: 
Sixteen clinical guidelines published between 2003-2015 met the inclusion criteria 
for specific mention of cost/economic evidence. More than 50% of these guidelines 
were published between 2006-2015. For indication, 3 out of 16 guidelines were for 
diabetes, while the rest were for different indications. In these16 guidelines “cost 
effectiveness” was mentioned 14 times, either referencing cost-effectiveness data 
or to mention the importance of such data for selecting treatment options. The 
guidelines commonly cite high cost of disease or high economic burden as one of 
the considerations for developing new recommendations (11 out of 16). Another 
term that was commonly used by these guidelines was “cost-benefit,” which was 
mentioned 5 times in these guidelines. Notably, QALY was rarely mentioned (1 out 
of 16 times) in these guidelines. ConClusions: This analysis suggests that some 
clinical experts groups are increasingly showing willingness to use and incorporate 
health economic information for developing new recommendations. Findings from 
this study might aid drug and device manufacturers in understanding the context of 
use of such information and allow them to tailor their product development plans 
for generating such evidence.
PHP12
ePidemiological data Presented in german benefit assessments – a 
comParison between PHarmaceutical comPanies and g-ba
El Malahi Z, Hirsch R, Boehler Y
Cologne University of Applied Sciences, Leverkusen, Germany
objeCtives: Dossiers for German benefit assessments on drugs require epidemio-
logical data. The number of statutory health insured patients in the target population 
is needed; basically the claimed number of patients with added benefit. This number 
is presented by pharmaceutical companies, evaluated/adapted during assessment 
and then included in G-BAs final decisions. The aim of this study is to compare the 
epidemiological data presented by companies and G-BA in order to assess deviations 
overall, by year and by therapeutic area. Time trends, susceptible therapeutic areas 
and possible reasons may be delineated. Methods: All relevant documents were 
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A517
number of expedited approval programs. The objective of this study was to evalu-
ate these programs by examining whether drugs included in them have provided 
larger health gains than drugs excluded from them. Methods: We considered the 
FDA’s priority review, accelerated approval, and fast-track programs. We estimated 
health gains in terms of quality-adjusted life-years (QALYs) for drugs approved 
for the first time between 1999 and 2011, relative to treatments available at the 
time of their approval. We identified QALY estimates from published cost-utility 
analyses, and comparative effectiveness studies that estimated relative effec-
tiveness using QALYs. We excluded studies that compared drugs to placebo or 
no treatment when an alternative active treatment was available, and to be con-
servative we excluded estimates from studies supported by the pharmaceutical 
industry. We compared QALY gains for drugs included in the designation pro-
grams vs. drugs excluded from them using Mann Whitney U tests. Results: We 
identified QALY gain estimates for 102 drugs, representing approximately 40% 
of drugs approved between 1999 and 2011. We included 15 of 37 drugs approved 
through accelerated approval, 54 of 149 drugs approved through priority review, 
and 24 of 65 drugs approved through fast-track designation. Drugs in the prior-
ity review program had mean QALY gains of 0.35 vs. -0.02 for drugs excluded 
(p= 0.011). Drugs included in the accelerated approval program had mean QALY 
gains of 0.43 vs. 0.13 for drugs excluded (p= 0.039). Drugs included in the fast-track 
designation program had mean QALY gains of 0.34 vs. 0.12 for drugs excluded 
(p= 0.014). ConClusions: This study suggests that drugs included by FDA in accel-
erated review programs have larger clinical gains than drugs excluded from the 
programs.
PHP19
cost of adverse drug events on HealtH resources utilizaton in 
older adult singaPoreans
Chen LL, Krishnan SS, Gui HS, Ong KY, Mamun K
Singapore General Hospital, Singapore, Singapore
objeCtives: Adverse drug effects (ADE) and their subsequent injuries lead to 
increased health resources utilization in older populations. This study aimed to 
(i) evaluate the types of ADE-related hospitalizations, (ii) analyze the associ-
ated costs of hospitalizations and length of stay. Methods: A retrospective, 
single-center observational study was conducted at an academic medical 
center in Singapore. Records of hospitalizations with diagnoses related to ADEs 
between January 2006 and December 2013 were identified using the International 
Classification of Diseases, Ninth and Tenth Revision, Clinical Modification (ICD-9 
and 10) codes. Summary statistics were used to report patient demographics, 
diagnoses, costs of hospitalizations (Singapore dollars, SGD$) and length of hos-
pital stay (LOS) in days. Results: The analysis included a total of 3088 patients 
aged ≥ 65 years old. The median age was 75 (IQR, 71-81) and majority were female 
(59.1%). The median cost of hospitalizations was $1014.65 (IQR, $607.65- $2003.40) 
and the median length of stay was 4 days (IQR, 2-8). The top five causative drug 
classes for ADE-related hospitalizations were diuretics (31.3%), anticoagulants 
(21.3%), anti-hypertensive (11.6%), anti-infective (5.6%) and anti-neoplastic (4.8%). 
Multivariate linear regression showed that anti-infectives are associated with 
longer LOS and higher total bills compared to the other four ADE-related admis-
sions i.e., 4.8 days longer (p< 0.001) and SGD$3734.90 more in cost (p< 0.001). This 
could be due to the various therapeutic monitoring parameters associated with 
anti-infective use, and a switch of therapy to more expensive alternatives should 
antibiotic resistance occur. ConClusions: ADE-related hospitalizations caused 
significant expenditure and morbidity in older population. Further efforts are nec-
essary to improve pharmacotherapy and relieve health care payers of preventable 
treatment costs. Multiple measures to prevent ADE-related hospitalizations such 
as electronic alerts, improving incidence reporting system, involving pharmacists 
to aid in prescribing decision and improving nursing administration of medica-
tions may potentially address this issue.
PHP20
advanced tHeraPy medicinal Products may dramatically imPact 
Payers’ budget
Hanna E1, Rémuzat C1, Auquier P2, Toumi M3
1Creativ-Ceutical, Paris, France, 2Université de la Méditerranée, Marseille, France, 3Aix-Marseille 
University, Marseille, France
objeCtives: Advanced therapy medicinal products (ATMPs) are innovative thera-
pies that encompass gene therapy, somatic cell therapy, and tissue engineered prod-
ucts. These therapies are expected to bring important health benefits, but also to 
substantially impact the pharmaceuticals budget. The aim of this study was to 
characterize ATMPs in development and discuss future implications in terms of 
market access. Methods: Clinical trials were searched in EUdraCT, clinicaltrials.
gov and ICTRP databases. Trials were classified by category of ATMPs as defined 
by European regulation EC N° 1394/2007, as well as by development phase and 
therapeutic area. Results: 939 clinical trials investigating ATMPs were identified 
(85% ongoing, 15% completed). Majority of trials were in early stages (phase I, I/II, 
II: 92%; phase II/III, III: 8%). Per category of ATMPs, we identified 53.6% of trials for 
somatic cell therapies, 22.8% for tissue engineered products, 22.4% for gene thera-
pies, and 1.2% for combined products (incorporating medical device). Therapeutic 
areas included cancer (24.8%), cardiovascular and blood diseases (21.5%), muscu-
loskeletal disorders (10.5%), immune system and inflammation (9.4%), neurology 
(9.1%) and others. 47.2% of trials enrolled less than 25 patients. Due to complexity 
and specificity of ATMPs, new clinical trial methodologies are being considered (e.g. 
small sample size, non-randomised trials, single arm trials, surrogate endpoints, 
integrated protocols, and adaptive designs). Evidence generation post-launch will 
become unavoidable to address payers’ expectations. ConClusions: ATMPs rep-
resent a fast growing field of interest. Although most of the products are in early 
development phase, the combined trial phase and the potential to cure severe 
chronic conditions suggest that ATMPs may reach the market earlier than stand-
ard therapies. Targeted therapies opened up the way for new trial methodologies, 
as well as the influence of patient copayments on the market shares of patented 
medications. Methods: We used data about on-patent volume, patient additional 
copayment, total pharmaceutical expenditure, and expenditure for on-patent medi-
cines. Data for expenditure were approached by sales. The database was derived 
from the Greek National Organization for Medicines (EOF), and Greece’s main health 
insurance fund (EOPYY). The data were selected on the basis of the therapeutic 
categories that include active substances under patent protection. Our empirical 
investigation was based on a linear regression, an exponential form equation, and a 
quadratic regression. Results: Our analysis suggests that pharmaceutical spend-
ing is significantly and positively associated with the volume of on-patent medi-
cines. According to the second regression analysis, patient additional copayment 
is positively related to spending for on-patent medicines. The relationship between 
the cumulative penetration of on-patent medicines and the share of the relevant 
expenditure on the total pharmaceutical expenditure was found positive and statisti-
cally significant. ConClusions: According to our empirical findings, the increasing 
penetration of on-patent medicines during 2001-2014 contributed significantly to 
the pharmaceutical spending increase, while the increase of spending for on-patent 
medicines increases the average additional copayment. However, further research 
regarding the extent to which the health effects of these medicines outweigh the high 
cost is essential for taking evidence-based reimbursement decisions.
PHP16
analysis of biotecHnology drugs market in turkey
Gursoy K, Ozturk Y, Demir C, Celik HD, Koselerli R, Dogru ST
Turkish Social Security Institution, Ankara, Turkey
objeCtives: Biotechnology drugs (BD) help extending lives, slowing and prevent-
ing disease progression, combating debilitating and rare diseases, reducing hos-
pitalization, and improving quality of life. However, at the same time they assert 
greater burden on the public finances with their high prices. This study analyzes 
how spending on BD evolved in Turkey, then shows how much it contributed on 
the growth of the total budget, and finally suggests policies maintaining future 
sustainability. Methods: Claims data from Turkish Social Security Institution 
(SGK) for all ambulatory care drugs reimbursed were collected in the period of 
January 2007 to December 2014 and drugs defined as BD were decided among all 
reimbursed drugs. Spending on BD, their share on overall budget, and distribu-
tion of BD in terms of ATC classification were all computed. Results: Number 
of BD reimbursed by SGK in 2014 reached to 202 from 107 in 2007, meaning that 
on average 14 new drugs were added to the reimbursement list yearly. While BD 
only represented 7.2% of the total public drug spending in 2007, the figure skyrock-
eted to 17.4% in 2014. Average annual growth rate for BD spending and aggregate 
spending were 23% and 8% respectively. In addition, between 2007 and 2014 total 
amount paid to BD hiked by 316%, but overall budget went up only 73% in the 
same period. ATC-L (Antineoplastic and immunomodulating agents) received the 
largest share (52%) from bio-spending, followed by ATC-A (alimentary tract and 
metabolism), and ATC-B (blood and blood forming organs), all three constituting 
nearly 90%. ConClusions: There has been an increasing trend in BD spending 
in Turkey, threating the sustainability of drug budget. Hence introducing new 
policies is of great importance. Leaving a larger room for those drugs, considering 
value-based pricing, and developing risk sharing agreements can be listed as the 
main policy recommendations for Turkey.
PHP17
costs of adverse drug events: systematic review
Batel-Marques F1, Penedones A2, Alves C1, Mendes D2
1University of Coimbra, Coimbra, Portugal, 2AIBILI, Coimbra, Portugal
objeCtives: Adverse drug events (ADE) have a considerable adverse impact on 
human health, and have been associated with increased healthcare costs. Several 
studies addressed the economic burden of drug-related morbidity, but, to date, 
no attempt has been made to estimate the average costs of ADE. The aim of this 
systematic review is to estimate costs related with ADE. Methods: MEDLINE and 
Cochrane Library were searched from 1995 up to 2015. Experimental and obser-
vational studies, economic evaluations and systematic reviews were included. 
Methodological quality of selected studies was assessed by Cochrane Collaboration 
tool for experimental and observational studies, Evers Checklist for economic evalu-
ations and PRISMA guideline for systematic reviews. Studies were classified accord-
ing to the setting analyzed in “Ambulatory”, and “Hospital”. Costs were classified as 
“Direct” and “Indirect”. Data were analyzed using descriptive statistics. Results: 
Forty-one (82%) observational studies, 5 (10%) economic evaluations and 4 (18%) 
systematic reviews were included. Economic evaluations were the type of study 
assessed with the highest methodological quality score. The mean study duration 
was 29 months [2 weeks–127 months]. Most of the studies assessed the median 
costs of any ADE (n= 30; 60%). Thirty-three (66%) studies evaluated any therapeutic 
group. Thirty-two (64%) studies estimated costs of ADE in “Hospital” setting. “Direct 
medical costs” were the most frequently type of costs evaluated (n= 26; 84%). The 
unit of measure and the way how the costs were estimated varied widely across the 
studies. ConClusions: Several studies have investigated the costs related with 
ADE. However, due to the wide variety of study methodology, settings analyzed, and 
type and unit of measurement of costs evaluated, no conclusions can be drawn. 
Further work is warranted to standardize this type of study in order to properly 
estimate the economic burden of ADE.
PHP18
fast-tracking innovation: a scorecard for tHe fda’s exPedited 
review Process
Chambers J1, Thorat T1, Chenoweth MD1, Neumann PJ2
1Tufts Medical Center, Boston, MA, USA, 2Center for the Evaluation of Value and Risk in Health, 
Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA
objeCtives: The United States Food and Drug Administration (FDA) accelerates 
the review of drugs that show potential to treat serious conditions through a 
